Pfizer: primary vaccinations completed for VALOR trial
(CercleFinance.com) - Pfizer and Valneva announce the completion of the primary vaccination series (three doses) with the Lyme disease vaccine candidate, VLA15, for participants in the Phase III VALOR trial, patients who will be followed until the end of the 2025 Lyme disease season.
This trial will be conducted at several sites in regions of the USA, Canada and Europe where Lyme disease is highly endemic. A booster vaccination will be performed approximately one year after the completion date of the primary vaccination.
Subject to positive data, Pfizer plans to submit marketing authorization applications to the U.S. FDA and the European Medicines Agency in 2026. Pfizer and Valneva have signed a co-development agreement for VLA15 in April 2020.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This trial will be conducted at several sites in regions of the USA, Canada and Europe where Lyme disease is highly endemic. A booster vaccination will be performed approximately one year after the completion date of the primary vaccination.
Subject to positive data, Pfizer plans to submit marketing authorization applications to the U.S. FDA and the European Medicines Agency in 2026. Pfizer and Valneva have signed a co-development agreement for VLA15 in April 2020.
Copyright (c) 2024 CercleFinance.com. All rights reserved.